Beta Bionics (NASDAQ:BBNX) CFO Sells 5,104 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 5,104 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $17.05, for a total transaction of $87,023.20. Following the completion of the sale, the chief financial officer owned 165,931 shares in the company, valued at $2,829,123.55. The trade was a 2.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Feider also recently made the following trade(s):

• On Monday, June 29th, Stephen Feider sold 4,896 shares of Beta Bionics stock. The stock was sold at an average price of $17.03, for a total transaction of $83,378.88.
• On Tuesday, June 2nd, Stephen Feider sold 6,676 shares of Beta Bionics stock. The stock was sold at an average price of $12.61, for a total transaction of $84,184.36.

Beta Bionics Stock Performance

Shares of NASDAQ BBNX traded down $1.33 during trading on Tuesday, hitting $15.67. The company had a trading volume of 931,657 shares, compared to its average volume of 1,141,549. Beta Bionics, Inc. has a 52 week low of $8.80 and a 52 week high of $32.71. The business’s 50-day moving average is $12.23 and its 200 day moving average is $15.41. The company has a market cap of $698.29 million, a P/E ratio of -10.38 and a beta of 3.40.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%.The firm had revenue of $27.63 million for the quarter. On average, research analysts expect that Beta Bionics, Inc. will post -2.22 EPS for the current year.

Hedge Funds Weigh In On Beta Bionics

Several institutional investors and hedge funds have recently modified their holdings of BBNX. Eventide Asset Management LLC raised its holdings in shares of Beta Bionics by 0.8% during the fourth quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock worth $152,233,000 after acquiring an additional 37,476 shares in the last quarter. Farallon Capital Management LLC boosted its position in Beta Bionics by 2.6% during the third quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock valued at $85,718,000 after purchasing an additional 110,000 shares during the last quarter. Soleus Capital Management L.P. grew its stake in Beta Bionics by 12.5% in the second quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock valued at $55,622,000 after purchasing an additional 424,817 shares in the last quarter. Vanguard Group Inc. grew its stake in Beta Bionics by 213.5% in the third quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock valued at $44,036,000 after purchasing an additional 1,509,217 shares in the last quarter. Finally, Eversept Partners LP increased its position in Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after purchasing an additional 736,576 shares during the last quarter.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Weiss Ratings cut Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. The Goldman Sachs Group reduced their price objective on Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. Leerink Partners lowered their target price on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 22nd. Finally, Bank of America dropped their target price on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Beta Bionics has a consensus rating of “Moderate Buy” and an average price target of $19.70.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.